Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07654296 · ClinicalTrials.gov registry record · Phase 3
Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT07654296 is a Phase 3 study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 100 participants.
The verdict
NCT07654296, a Phase 3 study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters.
Interventions
- DRUG Suzetrigine
- DRUG multimodal analgesia regimen without suzetrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07654296
The ClinicalTrials.gov registry entry for NCT07654296 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Suzetrigine is the first listed.
NCT07654296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07654296 about?
NCT07654296 is a clinical study titled "Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery". Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for ...
What is the current status of trial NCT07654296?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2026-08-01. Estimated completion is 2027-03-31.
What interventions are being tested in trial NCT07654296?
The interventions under investigation include: Suzetrigine (DRUG), multimodal analgesia regimen without suzetrigine (DRUG).
Who is sponsoring clinical trial NCT07654296?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.